Appendix C
ARB Prioritization Scheme
Categories and Point Distribution

		Point Distribution
1.	**IARC/U.S. EPA cancer classifications (The definitions of each IARC or U.S. EPA classification are attached.):**	
	IARC Group 1 or U.S. EPA Group A	4
	IARC Group 2A or U.S. EPA Group B1	3.5
	IARC Group 2B or U.S. EPA Group B2	3
	IARC Group 3 or U.S. EPA Group C	1
	IARC Group 4 or U.S. EPA Group D	0
2.	**Number of known organ systems affected:**	
	4 or more	4
	3	3
	2	2
	1 or Unknown	1
	No effect on an organ system considered significant	0
3.	**Cancer unit risk (approved unit risk value) ($\mu g/m^3)^{-1}$ multiplied by California emissions (primarily emissions reported under the AB 2588 "Hot Spots" program were used) (μg/year):**	
	10^{10}	8
	10^9 but $< 10^{10}$	7
	10^8 but $< 10^9$	6
	10^7 but $< 10^8$	5
	10^6 but $< 10^7$	4
	10^5 but $< 10^6$	3
	10^4 but $< 10^5$	2
	10^3	1
	No California emissions data or cancer unit risk value	0
4.	**California emissions / chronic Reference Exposure Level:**	
	10^{15}	4
	10^{12} but $< 10^{15}$	3
	10^{10} but $< 10^{12}$	2
	$< 10^{10}$	1
	No Reference Exposure Level or California emissions data	0

Appendix C (continued)
ARB Prioritization Scheme
Categories and Point Distribution

5. Chronic, acute, reproductive or developmental toxicity (noncancer effects):

Substance has 2 of the 3 listed effects	4
Substance has only chronic effects	2
Substance has only acute effects	2
Substance has only reproductive or developmental toxicity effects	2
No noncancer effects known	0

6. Availability of ambient monitoring data:

6 or more months of monitoring data	4
Less than 6 months of monitoring data or monitoring to begin within 6 months	3
At least 6 month needed to develop monitoring method	2
At least 1 year needed to develop monitoring method	1
Difficulties in developing monitoring method	0

7. Atmospheric persistence, bioaccumulation, and photochemical generation:

Substance bioaccumulates/persists in the environment and is photochemically generated	4
Substance bioaccumulates/persists in the environment	3
Substance is photochemically generated	2
Substance does not bioaccumulate/persist in the environment nor is photochemically generated	0

8. AB 2588 risk assessment considerations:

<u>Cancer considerations</u>

Compound drives 50% or more of the cancer risk in:

Over 5% of the risk assessments	2
3% to 5%	1.5
1% to 2% (or is the driver in at least 1)	1
None	0

Compound contributes to the overall cancer risk in:

Over 25% of the risk assessments	2
5% to 25%	1.5
1% to 4% (or contributes to at least 1)	1
None	0

Appendix C (continued)
ARB Prioritization Scheme
Categories and Point Distribution

Noncancer considerations	
Compound has the highest hazard index in:	
Over 5% of the risk assessments	2
3% to 5%	1.5
1% to 2% (or has the highest hazard index in at least 1)	1
None	0
Compound contributes to the overall noncancer risk in:	
Over 20% of the risk assessments	2
5% to 20%	1.5
1% to 4%	1
None	0